Complicated drug still under review

The TGA has confirmed that Apellis' eye drug Syfovre is still being considered and that no decision has yet been made after Europe's advisory committee, the CHMP, refused granting the company marketing authorisation yet again this month.

To see the whole article please log in.

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here